Articles tagged with Type 1 Diabetes
A new large-scale longitudinal study will investigate the environmental, lifestyle, social, and clinical factors affecting brain development in children with type 1 diabetes. The five-year study aims to refine clinical guidelines and targeted treatments for children with diabetes.
Researchers found that semaglutide and tirzepatide led to significant weight loss (9.1% and 21.4%, respectively) and improved blood sugar control in patients with type 1 diabetes. Weight loss was associated with reduced insulin dose, indicating improved insulin resistance.
A new study found that adults with type 1 diabetes are hesitant to exercise due to fear of hypoglycaemia, a concern exacerbated by limited understanding of insulin dose adjustments and carbohydrate intake for physical activity. Education on exercise safety and dialogue within clinics can help break down barriers.
A new hybrid closed-loop technology has been shown to enable people with type 1 diabetes to run marathons with excellent glucose control. The technology, called AID system, automates insulin delivery based on sensor glucose values, allowing for safer and healthier lives.
A new class of weekly insulin, efsitora alfa, has been shown to be non-inferior to daily injections in managing blood sugar levels in patients with type 1 diabetes. However, the study found higher rates of hypoglycaemia, highlighting the need for vigilance in dose initiation and optimization.
Research links impaired circadian heart rate fluctuations to microvascular disease and increased long-term risk of cardiovascular mortality in people with diabetes. Disrupted daily heart rate variations are associated with a doubled risk of dying from cardiovascular causes.
Researchers found that altitude changes during flights may cause slight increases and decreases in insulin delivery, potentially leading to blood glucose fluctuations. Individuals using insulin pumps should be aware of these effects and consider temporarily disconnecting their pumps before take-off.
Research suggests that eating fruit, oats, and rye in childhood increases the risk of developing type 1 diabetes, but consuming berries may lower this risk. The study followed thousands of children in Finland from birth to age six and found associations between specific foods and an increased or decreased risk of islet autoimmunity.
Scientists discovered the highest natural blood sugar levels in mammals, found in a species of bats that can survive on a diet rich in sugars. The study's findings suggest that these bats have evolved unique strategies for glucose regulation, which may hold potential for managing metabolic diseases in humans.
Researchers found that people with chronic diabetes complications are up to three times more likely to have a mental health condition, while those with mental health disorders are up to two and a half times more likely to experience sustained diabetes complications. The study highlights the importance of screening for both risk factors.
Texas A&M researchers are investigating the use of extracellular vesicles to deliver immune-suppressing proteins, potentially reducing the immune system's attack on insulin-producing beta-cells. The goal is to develop a novel treatment for type 1 diabetes, which currently has only lifelong insulin therapy as an approved option.
Research suggests that exposure to type 1 diabetes in the womb confers long-term protection against the condition in children with affected mothers, but not fathers. The study found a relative risk of 1.8 for children diagnosed with T1D if their father has the condition compared to those with affected mothers.
A recent paper surveys advances in diabetes pathogenesis and treatment, highlighting the role of genes, environmental factors, and social determinants. The study suggests that understanding these dynamics is key to developing targeted interventions to reduce diabetes risk and manage its complications.
The risk of developing type 1 diabetes (T1D) decreases in girls after age 10, while the risk in boys remains stable. Males with a single autoantibody have a significantly higher risk of T1D than their female counterparts.
Children diagnosed with type 1 diabetes are at significantly higher risk of mood and anxiety disorders, as well as behavioral syndromes. The study highlights the urgent need for monitoring and support for their mental health.
A follow-up study found that COVID-19 infection accelerated the progression from pre-symptomatic to clinical type 1 diabetes in youth, with no observed effect in adults. Further research is needed to determine whether vaccination and monitoring for COVID-19 symptoms can help prevent or delay this progression.
Researchers identified two distinct T-cell signatures in children with newly diagnosed type 1 diabetes and those at risk of developing the disease. These signatures may serve as potential biomarkers and targets for preventive immunotherapy treatments.
Researchers from Mount Sinai and City of Hope demonstrate a combination treatment that increases human insulin-producing beta cells by 700% in mice with diabetes. This breakthrough could lead to new treatments for the hundreds of millions of people with diabetes worldwide.
A six-year study found that consuming diets more closely aligned with the Mediterranean and DASH diets can lower levels of harmful blood markers and reduce cardiovascular disease risk. These dietary patterns emphasize plant-based foods, healthy fats, lean proteins, and low intake of processed foods and sugars.
The number of people aged 65 and older with type 1 diabetes increased from 1.3 million to 3.7 million between 1990 and 2019, while death rates fell by 25%. However, substantial global inequalities in diabetes care persist, with higher mortality rates in low- and middle-income countries.
A new study led by researchers at UC San Francisco found that a virtual emotion-centered program called TunedIn can reduce diabetes distress by half and improve glucose control. The program incorporates elements of Acceptance and Commitment Therapy and was delivered virtually to 276 adults with Type 1 diabetes.
Aging human pancreatic beta cells display features of senescence but maintain elevated levels of genes crucial for function and exhibit an ability to release insulin in response to glucose. This sheds light on the potential role of aging beta cells in immune regulation and their relevance to autoimmune reactions in type 1 diabetes.
A new study aims to investigate whether vaccination against SARS-CoV-2 can protect children at increased genetic risk of developing type 1 diabetes. The AVAnT1A Study, the largest intervention study to date, examines the relationship between viral infections and early childhood development.
A new NIH grant will investigate biological processes that contribute to defects in immune response in the eyes of those with diabetes. Researchers aim to understand why diabetic patients are more susceptible to corneal infections and identify methods to reverse these effects.
Researchers have discovered a repurposed cancer drug that can convert acinar cells into insulin-producing cells, which could provide a new avenue for treating diabetes. The treatment partially improved hyperglycemia and persisted without additional treatment in diabetic mice and non-human primates.
An experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, lengthening their lifespan. The drug targets insulin-making beta cells directly and shields them from immune system attacks, raising the possibility of a new treatment for the autoimmune condition.
Adults with type 1 diabetes who use modern hybrid insulin pumps experience significant improvements in blood sugar levels, reducing the risk of organ damage by up to three hours per day. The treatment also reduces the time spent with low blood sugar levels and is associated with high patient satisfaction.
Researchers found a unique genetic mutation in the PD-L1 gene, essential for preventing autoimmune diabetes. The discovery sheds light on the role of PD-L1 in regulating immune cells and could lead to new treatments for the devastating disease.
A low-fat vegan diet was found to reduce insulin needs by 28% and improve insulin sensitivity by 127% in people with type 1 diabetes, according to a groundbreaking new study. The diet also led to improvements in cholesterol levels, kidney function, and weight.
Studies at the University of Gothenburg found a clear shift in arterial disease risks in diabetes, with decreases in central organ diseases like heart attack and stroke, but increases in peripheral vessel complications. Closer monitoring of long-term blood sugar levels can reduce peripheral arterial disease risk by 30-50%.
Leading investigators are creating a one-stop resource for human pancreatic data, standardizing and disseminating curated information on the human pancreas to foster collaborative and reproducible diabetes research. The PanKbase program aims to provide machine-actionable data following FAIR principles.
Researchers found that a high-fat diet suppresses the expression of a key protein in the gut, leading to inflammation and increased risk of Alzheimer's. Managing diabetes may be key to preventing or slowing down dementia symptoms.
A new study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes, showing significant weight loss and improved glucose control. Tirzepatide also reduces insulin dose and increases time-in-range on continuous glucose monitoring.
Women with selected rheumatic diseases experience a higher prevalence of childlessness, while risks for pre-eclampsia, low birth weight, and preterm delivery are increased for many conditions. Men with rheumatic conditions also face a higher risk of childlessness, although the impact on fertility varies among different diseases.
A new study reveals that glucose fluctuations affect cognitive function in people with Type 1 Diabetes, but individuals differ in their susceptibility. The researchers found that minimizing glucose fluctuations is crucial for optimizing processing speed, especially for older adults and those with certain health conditions.
Researchers have developed a novel immunotheraphy targeting macrophages to induce tolerance in type 1 diabetes, demonstrating its potential as a curative treatment. The therapy also shows promise for other autoimmune diseases, with results suggesting no impact on the immune system's ability to capture and process liposomes.
The University of Arizona College of Medicine – Tucson has received a $2.7 million grant from the Juvenile Diabetes Research Foundation to test an implantable device that could eliminate the need for glucose testing and insulin injections in people with Type 1 diabetes. The device, developed by Professor Klearchos Papas, uses oxygen-en...
Groundbreaking research reveals changes in pancreatic beta cells at the onset of Type 1 Diabetes, identifying a novel mechanism for protection and a promising therapeutic target in mice and humans. Boosting levels of METTL3 enzyme may slow disease progression.
Healthcare providers must prioritize patient experience to improve diabetes care. This includes explaining treatment options and considering each patient's level of health literacy and cultural background.
A study found that 670 nanometres of red light stimulated energy production within mitochondria, leading to increased glucose consumption and a 27.7% reduction in blood glucose levels. This non-invasive technique has the potential to impact diabetes control by reducing damaging fluctuations of blood glucose.
A multicenter study found that a small pancreas size predicts a faster progression to stage 3 Type 1 diabetes. The study also suggests that using pancreas volume measurement combined with validated metabolic risk measures can more accurately predict disease development than either method alone.
A global study review found negative indirect impacts of the pandemic on people with diabetes, including a rise in non-COVID-19-related deaths, diabetic ketoacidosis among children and adolescents, and sight loss. Pediatric ICU admissions were also significantly increased.
Researchers have developed a new oral insulin medicine that uses nano-carriers to protect insulin from stomach acid, allowing for precise delivery to the liver and reducing the risk of hypoglycemia. This innovation has been successfully tested on baboons, mice, and rats with diabetes, paving the way for human trials starting in 2025.
A new study published in Nature Communications found that AI-driven eye exams can close care gaps among racial and ethnic minority youth with diabetes, populations with historically higher rates of diabetic retinopathy. The technology uses cameras to take pictures of the back of the eye without dilation and provides immediate results.
Researchers have successfully genetically modified pluripotent stem cells to evade immune recognition, offering a viable path forward for pluripotent stem cell-based therapies. The study's findings suggest that these engineered stem cells could pave the way for new treatments for diseases such as Type 1 diabetes and macular degeneration.
A study of 620,000 children found that maternal type 1 diabetes was associated with increased risk for most types of congenital heart defects in offspring. Obesity and overweight were linked to increased risk for complex defects, such as outflow tract obstruction, while decreasing the risk for ventricular septal defects.
A recent study by the Hebrew University proposes a new etiology for early stages of type 1 diabetes, attributing it to disrupted RNA editing within pancreatic beta cells. This perspective challenges long-held beliefs about viral involvement, suggesting potential implications for treatments and cures.
A moderate low-carbohydrate diet has been shown to lower average blood sugar levels and increase time spent within the target glucose range without adverse effects. Participants experienced improved glucose control and felt more satisfied with the new diet.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers at the University of Alberta and Cornell University have developed a device that can secrete insulin under the skin, improving cell survival and diabetes reversal in mice. The innovative approach called SHEATH avoids immunosuppression, making transplants safer for patients with type 1 diabetes.
Researchers found that vaccination of neonatal mice with group A Streptococcus promotes clonal expansion of innate-like B cells producing antibody against N-acetyl-D-glucosamine (GlcNAc), reducing Type 1 diabetes risk. These GlcNAc-specific B-1 B cells aid in producing tolerance, facilitating efficient clearance of apoptotic beta cells...
The international consensus report on precision diabetes medicine highlights significant advancements in prevention, diagnosis, treatment, and prognosis. The report also sheds light on knowledge gaps and provides a framework for future research.
Researchers from Cornell and University of Alberta have developed an under-the-skin implant that can secrete insulin without immunosuppression. The approach offers an easier alternative to traditional transplants or insulin injections, with the potential for long-term management of Type I diabetes.
A new clinical trial has shown that a stem cell-based device can reduce the amount of insulin required for some participants with Type 1 diabetes. The device, developed by ViaCyte, aims to replace the insulin-producing beta cells that people with the condition lack.
Researchers discover a unique gene, ZNF808, crucial for human pancreas development, contrasting with its absence in other animals. This finding could aid the search for a Type 1 diabetes cure by understanding how humans differ from other species.
Researchers analyzed FDA and patent records to find that manufacturers extended market exclusivity by filing additional patents after FDA approval and obtaining patents on delivery devices. This resulted in a median of 16 years of protection, surpassing other top-selling small-molecule drugs.
Researchers are developing a bioengineered pancreas-like tissue using innovative biomaterials and engineered cells. The goal is to implant these cell-laden scaffolds into patients who need help managing their glucose levels.
A comprehensive review study identifies emerging biomarkers that mirror efforts to halt beta-cell autoimmunity, offering potential applications in clinical practice. The study's findings may improve the management of type 1 diabetes during its partial remission phase.
A team of MSU researchers, supported by a $750,000 grant from JDRF, is creating a new approach to image immune cells in living subjects. This could enable better treatment opportunities and outcomes for patients with Type 1 diabetes, particularly those who are eligible for cell transplantation strategies.
Researchers at the University of Alberta have created a new process to produce insulin-producing pancreatic cells from patient stem cells, achieving a 90% success rate. The breakthrough could lead to injection-free glucose control in people with diabetes and eliminate the need for anti-rejection drugs.